These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23768748)

  • 1. Boceprevir for HCV in patients with HIV: where next?
    Osinusi A; Naggie S
    Lancet Infect Dis; 2013 Jul; 13(7):563-4. PubMed ID: 23768748
    [No Abstract]   [Full Text] [Related]  

  • 2. Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
    Rivero-Juarez A; Lopez-Cortes LF; Girón-Gonzalez JA; Pineda JA; Rivero A;
    Lancet Infect Dis; 2014 Jan; 14(1):13-14. PubMed ID: 24355031
    [No Abstract]   [Full Text] [Related]  

  • 3. HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome.
    Reddy KR; Wirjosemito A; Pavri TM; Sinese L
    Transplantation; 2014 Apr; 97(8):e47-8. PubMed ID: 24732900
    [No Abstract]   [Full Text] [Related]  

  • 4. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
    Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D
    J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712
    [No Abstract]   [Full Text] [Related]  

  • 5. Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.
    Mandorfer M; Steiner S; Schwabl P; Payer BA; Aichelburg MC; Lang G; Grabmeier-Pfistershammer K; Trauner M; Peck-Radosavljevic M; Reiberger T
    J Infect Dis; 2015 Mar; 211(5):729-35. PubMed ID: 25214517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
    Flamm SL; Lawitz E; Jacobson I; Bourlière M; Hezode C; Vierling JM; Bacon BR; Niederau C; Sherman M; Goteti V; Sings HL; Barnard RO; Howe JA; Pedicone LD; Burroughs MH; Brass CA; Albrecht JK; Poordad F
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current indications for triple therapy in hepatitis C virus infection].
    Molina Pérez E; Fernández Castroagudín J; Domínguez Muñoz E
    Gastroenterol Hepatol; 2012 Apr; 35(4):266-77. PubMed ID: 22410706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM;
    HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
    Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP
    J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
    Soriano V; Sherman KE; Rockstroh J; Dieterich D; Back D; Sulkowski M; Peters M
    AIDS; 2011 Nov; 25(18):2197-208. PubMed ID: 21866039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
    Jacobson IM; Marcellin P; Zeuzem S; Sulkowski MS; Esteban R; Poordad F; Bruno S; Burroughs MH; Pedicone LD; Boparai N; Deng W; DiNubile MJ; Gottesdiener KM; Brass CA; Albrecht JK; Bronowicki JP
    Hepatology; 2012 Aug; 56(2):567-75. PubMed ID: 22619063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
    Vierling JM; Zeuzem S; Poordad F; Bronowicki JP; Manns MP; Bacon BR; Esteban R; Flamm SL; Kwo PY; Pedicone LD; Deng W; Dutko FJ; DiNubile MJ; Koury KJ; Helmond FA; Wahl J; Bruno S
    J Hepatol; 2014 Aug; 61(2):200-9. PubMed ID: 24747798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Triple combination treatment of chronic hepatitis C].
    Husa P
    Vnitr Lek; 2012; 58(7-8):588-90. PubMed ID: 23067190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis.
    Shouval D
    J Hepatol; 2012 Feb; 56(2):303-4. PubMed ID: 22015961
    [No Abstract]   [Full Text] [Related]  

  • 15. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
    Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
    J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
    Chang MH; Gordon LA; Fung HB
    Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C therapy update.
    Casey LC; Lee WM
    Curr Opin Gastroenterol; 2012 May; 28(3):188-92. PubMed ID: 22476156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dual infection with HIV and HCV. Focus on antiviral therapy].
    MMW Fortschr Med; 2001 Oct; 143(40):54. PubMed ID: 11692848
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination treatment for chronic HCV hepatitis in lymphangioleiomyomatosis: first case report.
    Bartalesi F; Camiciottoli G; Corti G; Maluccio NM; Biliotti E; Bartoloni A; Taliani G
    J Chemother; 2009 Feb; 21(1):110-1. PubMed ID: 19297285
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatitis C infection and presence of advanced fibrosis: wait or treat? Why wait? There is no time to lose, is there?
    Tillmann HL
    J Hepatol; 2013 Mar; 58(3):412-4. PubMed ID: 23247067
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.